Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding NSAID-PPI-COX-2 interrelationships.

Gurkirpal Singh1

  • 1Stanford University, Palo Alto, California, USA.

Drugs of Today (Barcelona, Spain : 1998)
|June 11, 2004
PubMed
Summary

Proton pump inhibitors (PPIs), like pantoprazole, effectively reduce gastrointestinal risks associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors in arthritis patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seizures in brain tumor hospitalizations in the United States.

Frontiers in neurology·2026
Same author

Cognitive debriefing of the Scleroderma Health Assessment Questionnaire in diffuse cutaneous systemic sclerosis.

Journal of scleroderma and related disorders·2025
Same author

Prevalence of Seizures in Hospitalizations with Traumatic Brain Injury: A U.S. Population-Based Study.

Neurotrauma reports·2025
Same author

Risk of Proximal Gastrointestinal Cancer After Positive Fecal Immunochemical Test.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2022
Same author

Age-Specific Rates and Time-Courses of Gastrointestinal and Nongastrointestinal Complications Associated With Screening/Surveillance Colonoscopy.

The American journal of gastroenterology·2021
Same author

Colorectal Cancer Incidence After Colonoscopy at Ages 45-49 or 50-54 Years.

Gastroenterology·2021

Area of Science:

  • Gastroenterology and Rheumatology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are common arthritis treatments but cause gastrointestinal (GI) issues.
  • Selective COX-2 inhibitors offer fewer GI complications but carry cardiovascular risks and aren't suitable for all patients.
  • Arthritis patients often have coronary artery disease risk and use low-dose aspirin, increasing GI event likelihood.

Purpose of the Study:

  • To evaluate the efficacy of proton pump inhibitor (PPI) therapy in mitigating NSAID-associated gastrointestinal complications.
  • To assess pantoprazole's role in healing existing NSAID-induced GI damage and preventing new lesions.
  • To examine the benefits of combining PPIs with NSAIDs or COX-2 inhibitors for high-risk patients.

Main Methods:

  • Review of recent randomized clinical trials and observational studies.
  • Analysis of data on pantoprazole's effectiveness in healing and preventing NSAID-induced GI damage.
  • Evaluation of combination therapy outcomes in patients with high GI risk or previous NSAID-related complications.

Main Results:

  • Pantoprazole therapy demonstrates effectiveness in healing NSAID-induced GI damage.
  • Pantoprazole successfully prevents gastrointestinal lesions during continuous NSAID use.
  • Combination therapy with PPIs and NSAIDs benefits high-risk patients, reducing rebleeding and dyspepsia.
  • Combining COX-2 inhibitors with PPIs shows promise for patients with prior NSAID-related GI issues.

Conclusions:

  • PPIs, particularly pantoprazole, are crucial for managing GI risks in patients using NSAIDs or COX-2 inhibitors.
  • Pantoprazole offers a protective strategy against NSAID-induced gastrointestinal damage and complications.
  • Combination therapy with PPIs provides a valuable approach for high-risk arthritis patients requiring anti-inflammatory treatment.

Related Experiment Videos